Ketoprofen
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ketoprofen: From Pain and Inflammation to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Ketoprofen is a long-established NSAID (propionic acid derivative) used for pain and inflammation associated with musculoskeletal conditions such as rheumatoid arthritis and osteoarthritis. The TxGNN model predicts it may be relevant to acromesomelic dysplasia, Hunter-Thompson type, a rare skeletal dysplasia, but this prediction is currently supported by no clinical trials and no published literature, and the model’s own rationale flags it as likely a knowledge-graph proximity artefact rather than a genuine mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pain and inflammation (general NSAID class use — e.g. rheumatoid arthritis, osteoarthritis); no UK-specific marketing authorisation on file in this evidence pack |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on general pharmacological knowledge, ketoprofen is a propionic acid derivative NSAID that inhibits COX-1/COX-2 to reduce prostaglandin synthesis, providing analgesic and anti-inflammatory effects. Its established efficacy is in inflammatory and painful musculoskeletal conditions.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare genetic skeletal disorder caused by GDF5 gene mutations, resulting in structural limb malformation. This is a developmental/structural condition rather than an inflammatory or pain-mediated pathology, so there is no obvious biological rationale connecting it to ketoprofen’s COX-inhibition mechanism.
The evidence pack’s own repurposing rationale is explicit on this point: it assesses the high TxGNN score as potentially arising from proximity bias in the knowledge graph (e.g. shared “skeletal/joint” nodes) rather than a true mechanistic connection. This prediction should therefore be treated with considerable caution and is not, on current evidence, a credible repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisation is currently on record for ketoprofen in this evidence pack (market status: Not marketed, 0 licences held). No product-specific information (brand, dosage form, licensed indication) is available to tabulate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is evidence level L5 — a model output with no supporting clinical trials or literature, and the mechanistic rationale itself suggests the score may reflect knowledge-graph bias rather than a genuine biological link. There is also a blocking data gap on UK/MHRA safety labelling (warnings, contraindications), meaning this candidate cannot yet pass an initial safety screen regardless of efficacy considerations.
To proceed, the following is needed:
- MHRA/SmPC warnings and contraindications data (currently a blocking gap)
- Confirmed mechanism of action data from DrugBank or equivalent source
- Any preclinical or case-level evidence specifically linking ketoprofen to skeletal dysplasia pathophysiology, to justify moving beyond model-only prediction
Note: Two other candidates in this evidence pack (not the top-ranked prediction) carry a more plausible mechanistic basis and may warrant separate follow-up as research questions rather than this rank-1 candidate: spondyloarthropathy, susceptibility to (L3, literature-supported, NSAIDs are a recognised class-level symptomatic treatment) and juvenile arthritis due to defect in LACC1 (L4, inflammatory joint disease with class-level NSAID plausibility). Neither has ketoprofen-specific trial or literature confirmation, but both are mechanistically more coherent than the rank-1 result reported above.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.